EA200501051A1 - Полимерный конъюгат биоактивного компонента ( варианты ), способ его получения и использования, фармацевтические продукты на его основе - Google Patents
Полимерный конъюгат биоактивного компонента ( варианты ), способ его получения и использования, фармацевтические продукты на его основеInfo
- Publication number
- EA200501051A1 EA200501051A1 EA200501051A EA200501051A EA200501051A1 EA 200501051 A1 EA200501051 A1 EA 200501051A1 EA 200501051 A EA200501051 A EA 200501051A EA 200501051 A EA200501051 A EA 200501051A EA 200501051 A1 EA200501051 A1 EA 200501051A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- conjugates
- receptor
- methods
- chemokines
- binding
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 5
- 238000002360 preparation method Methods 0.000 title abstract 2
- 230000000975 bioactive effect Effects 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 title 1
- 229940127557 pharmaceutical product Drugs 0.000 title 1
- 230000027455 binding Effects 0.000 abstract 6
- 102000005962 receptors Human genes 0.000 abstract 5
- 108020003175 receptors Proteins 0.000 abstract 5
- 102000019034 Chemokines Human genes 0.000 abstract 4
- 108010012236 Chemokines Proteins 0.000 abstract 4
- 102000004127 Cytokines Human genes 0.000 abstract 4
- 108090000695 Cytokines Proteins 0.000 abstract 4
- 102000015731 Peptide Hormones Human genes 0.000 abstract 4
- 108010038988 Peptide Hormones Proteins 0.000 abstract 4
- 239000003102 growth factor Substances 0.000 abstract 4
- 239000000813 peptide hormone Substances 0.000 abstract 4
- 229920000642 polymer Polymers 0.000 abstract 4
- 239000000203 mixture Substances 0.000 abstract 3
- 230000001270 agonistic effect Effects 0.000 abstract 1
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 238000010364 biochemical engineering Methods 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1808—Epidermal growth factor [EGF] urogastrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
- C08G63/02—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds
- C08G63/12—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds derived from polycarboxylic acids and polyhydroxy compounds
- C08G63/46—Polyesters chemically modified by esterification
- C08G63/48—Polyesters chemically modified by esterification by unsaturated higher fatty oils or their acids; by resin acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- AIDS & HIV (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
Abstract
Представлены способы синтеза полимерных конъюгатов цитокинов, хемокинов, факторов роста, полипептидных гормонов и их рецепторсвязывающих антагонистов, причем конъюгаты сохраняют необычайно высокую рецепторсвязывающую активность. Получение полимерных конъюгатов согласно способам, соответствующим данному изобретению, снижает до минимума или позволяет избежать стерического ингибирования взаимодействий рецептор-лиганд, которое обычно является результатом присоединения полимеров к рецепторсвязывающим участкам цитокинов, хемокинов, факторов роста и полипептидных гормонов, а также их агонистическим и антагонистическим аналогам. Изобретение представляет также конъюгаты и композиции, полученные данными способами. Конъюгаты, соответствующие данному изобретению, сохраняют повышенный уровень рецепторсвязывающей активности по сравнению с полученными традиционными способами связывания полимеров, которые не направлены на то, чтобы избежать рецепторсвязывающих доменов цитокинов, хемокинов, факторов роста и полипептидных гормонов. Конъюгаты, соответствующие данному изобретению, демонстрируют также увеличенный полупериод существования in vivo и in vitro по сравнению с неконъюгированным цитокинами, хемокинами, факторами роста и полипептидными гормонами. Данное изобретение представляет также наборы, содержащие данные конъюгаты и/или композиции, и способы использования таких конъюгатов и композиций во множестве диагностических, профилактических, терапевтических способов и биопроцессинге.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43602002P | 2002-12-26 | 2002-12-26 | |
US47991403P | 2003-06-20 | 2003-06-20 | |
PCT/US2003/041162 WO2004060300A2 (en) | 2002-12-26 | 2003-12-23 | Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity |
Publications (2)
Publication Number | Publication Date |
---|---|
EA200501051A1 true EA200501051A1 (ru) | 2007-02-27 |
EA013535B1 EA013535B1 (ru) | 2010-06-30 |
Family
ID=32717815
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200501051A EA013535B1 (ru) | 2002-12-26 | 2003-12-23 | Полимерный конъюгат биоактивного компонента (варианты), способ его получения и использования, фармацевтические продукты на его основе |
Country Status (19)
Country | Link |
---|---|
US (2) | US20040136952A1 (ru) |
EP (1) | EP1628618A4 (ru) |
JP (2) | JP2006519170A (ru) |
KR (1) | KR101162908B1 (ru) |
AU (1) | AU2003303636B2 (ru) |
BR (1) | BR0317752A (ru) |
CA (1) | CA2511815A1 (ru) |
CR (1) | CR7895A (ru) |
EA (1) | EA013535B1 (ru) |
EC (1) | ECSP055931A (ru) |
GE (1) | GEP20084487B (ru) |
IS (1) | IS7931A (ru) |
MX (1) | MXPA05006945A (ru) |
NO (1) | NO20053555L (ru) |
NZ (1) | NZ541122A (ru) |
PL (2) | PL380269A1 (ru) |
RS (1) | RS20050501A (ru) |
TW (1) | TWI364295B (ru) |
WO (1) | WO2004060300A2 (ru) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2549702C2 (ru) * | 2008-12-17 | 2015-04-27 | Мерк Шарп И Доум Корп., | Получение и применение моно- и ди-пэг il-10 |
EA029942B1 (ru) * | 2014-06-16 | 2018-06-29 | Общество С Ограниченной Ответственностью "Форт" (Ооо "Форт") | Стабильная фармацевтическая композиция на основе конъюгатов биологически активных белков с полиэтиленгликолем, содержащих азогруппу |
Families Citing this family (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2295450B1 (en) | 2000-09-29 | 2015-01-28 | Merck Sharp & Dohme Corp. | Pegylated interleukin-10 |
CA2464228C (en) | 2000-10-27 | 2017-01-17 | Immuno-Rx, Inc. | Vaccine immunotherapy for immune suppressed patients |
US20070025958A1 (en) | 2000-10-27 | 2007-02-01 | Hadden John W | Vaccine immunotherapy |
US20070154399A1 (en) * | 2000-10-27 | 2007-07-05 | Hadden John W | Immunotherapy for immune suppressed patients |
TWI406672B (zh) | 2002-12-26 | 2013-09-01 | Mountain View Pharmaceuticals | 生物效力增進的β干擾素聚合物共軛體 |
EP1628618A4 (en) * | 2002-12-26 | 2009-09-09 | Mountain View Pharmaceuticals | POLYMER CONJUGATES OF CYTOKINES, CHEMOKINS, GROWTH FACTORS, POLYPEPTIDE HORMONES AND ANTAGONISTS THEREOF WITH PRESERVED RECEPTOR BINDING ACTIVITY |
EP1625156B1 (en) * | 2003-05-12 | 2012-09-19 | Affymax, Inc. | Peptides that bind to the erythropoietin receptor |
EA010016B1 (ru) * | 2003-05-12 | 2008-06-30 | Афимакс, Инк. | Новые модифицированные полиэтиленгликолем соединения и их применение |
BRPI0411166A (pt) | 2003-05-12 | 2006-07-18 | Affymax Inc | composto compreendendo uma parcela de peptìdeo, uma parcela espaçadora e uma parcela de polìmero solúvel em água e composição farmacêutica compreendendo tal composto |
AU2004309083B2 (en) * | 2003-12-30 | 2010-11-11 | Augustinus Bader | Tissue regeneration method |
AU2005229001A1 (en) * | 2004-03-23 | 2005-10-13 | Amgen Inc. | Chemically modified protein compositions and methods |
ES2355642T3 (es) * | 2004-07-16 | 2011-03-29 | Nektar Therapeutics | Conjugados que comprenden una porcion de gm-csf y un polimero. |
WO2006062685A2 (en) * | 2004-11-11 | 2006-06-15 | Affymax, Inc. | Novel peptides that bind to the erythropoietin receptor |
MX2007005777A (es) * | 2004-11-11 | 2007-07-20 | Affymax Inc | Peptidos novedosos que se unen al receptor de eritropoietina. |
EP1674113A1 (en) * | 2004-12-22 | 2006-06-28 | F. Hoffmann-La Roche Ag | Conjugates of insulin-like growth factor-1 (IGF-1) and poly(ethylene glycol) |
CA2596706A1 (en) * | 2005-01-04 | 2006-07-13 | University Of Rochester | Blockade of elr+cxc chemokines as a treatment for inflammatory and autoimmune disease |
WO2007009208A1 (en) * | 2005-06-02 | 2007-01-25 | Cangene Corporation | Poly(ethylene glocol) modified human gm-csf with increased biological activity |
US8324159B2 (en) * | 2005-06-03 | 2012-12-04 | Affymax, Inc. | Erythropoietin receptor peptide formulations and uses |
US7919461B2 (en) | 2005-06-03 | 2011-04-05 | Affymax, Inc. | Erythropoietin receptor peptide formulations and uses |
US7550433B2 (en) | 2005-06-03 | 2009-06-23 | Affymax, Inc. | Erythropoietin receptor peptide formulations and uses |
WO2007014167A2 (en) * | 2005-07-22 | 2007-02-01 | Five Prime Therapeutics, Inc. | Compositions for and methods of treating epithelial diseases with growth factors |
US20080299072A1 (en) * | 2005-12-15 | 2008-12-04 | Laboratoires Serono Sa | Chemokine Antagonists |
CL2007002502A1 (es) * | 2006-08-31 | 2008-05-30 | Hoffmann La Roche | Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer. |
CN101484469B (zh) | 2006-08-31 | 2012-12-12 | 弗·哈夫曼-拉罗切有限公司 | 生产胰岛素样生长因子-ⅰ的方法 |
WO2008054585A2 (en) * | 2006-09-28 | 2008-05-08 | Schering Corporation | Use of pegylated il-10 to treat cancer |
TW200836761A (en) * | 2006-11-09 | 2008-09-16 | Novo Nordisk As | N-terminal pegylated prolactin receptor molecules |
EP1935428A1 (en) * | 2006-12-22 | 2008-06-25 | Antisense Pharma GmbH | Oligonucleotide-polymer conjugates |
DK2147116T3 (en) * | 2007-04-20 | 2016-05-30 | Sigma Tau Rare Disease Ltd | STABLE RECOMBINANT adenosine deaminase |
CA2707840A1 (en) | 2007-08-20 | 2009-02-26 | Allozyne, Inc. | Amino acid substituted molecules |
WO2009070639A1 (en) | 2007-11-28 | 2009-06-04 | Irx Therapeutics, Inc. | Method of increasing immunological effect |
AU2009231186A1 (en) * | 2008-04-03 | 2009-10-08 | F. Hoffmann-La Roche Ag | Pegylated insulin-like-growth-factor assay |
EP2303183A4 (en) | 2008-06-24 | 2015-11-04 | Bioactive Surgical Inc | SURGICAL TREATMENTS WORKED IN STEM CELLS OR OTHER BIOACTIVE MATERIALS |
AU2009200540A1 (en) * | 2008-07-03 | 2010-01-21 | Induce Biologics Inc. | Use of immobilized antagonists for enhancing growth factor containing bioimplant effectiveness |
MY156568A (en) * | 2008-07-31 | 2016-03-15 | Pharmaessentia Corp | Peptide-polymer conjugates |
KR20110042107A (ko) | 2008-08-07 | 2011-04-22 | 바이오엑티브 써지컬, 아이엔씨. | 의료 장치 및 이식물을 위한 줄기 세포 포획 및 고정화 코팅 |
CN102131518B (zh) | 2008-08-25 | 2016-01-20 | 百疗医株式会社 | 包含白介素-11类似物的生物聚合物缀合物 |
WO2010030366A2 (en) | 2008-09-11 | 2010-03-18 | Nektar Therapeutics | Polymeric alpha-hydroxy aldehyde and ketone reagents and conjugation method |
EP2341942A1 (en) | 2008-09-19 | 2011-07-13 | Nektar Therapeutics | Polymer conjugates of therapeutic peptides |
US8518888B2 (en) * | 2008-10-14 | 2013-08-27 | Csl Limited | Method of treatment of gastrointestinal-type cancer with antagonistic antibodies to IL-11R |
WO2010099003A2 (en) * | 2009-02-26 | 2010-09-02 | Oncolix, Inc. | Compositions and methods for visualizing and eliminating cancer stem cells |
US8648046B2 (en) * | 2009-02-26 | 2014-02-11 | Oncolix, Inc. | Compositions and methods for visualizing and eliminating cancer stem cells |
DK2429585T3 (en) | 2009-05-15 | 2018-07-30 | Irx Therapeutics Inc | VACCINE IMMUNOTHERAPY |
JP2011026294A (ja) * | 2009-06-26 | 2011-02-10 | Canon Inc | 化合物 |
US20110081398A1 (en) * | 2009-10-01 | 2011-04-07 | Tyco Healthcare Group Lp | Multi-mechanism surgical compositions |
US8968785B2 (en) * | 2009-10-02 | 2015-03-03 | Covidien Lp | Surgical compositions |
US20110081701A1 (en) * | 2009-10-02 | 2011-04-07 | Timothy Sargeant | Surgical compositions |
CA2820202C (en) | 2009-12-08 | 2018-06-12 | Irx Therapeutics, Inc. | Method of reversing immune suppression of langerhans cells |
AU2011268310A1 (en) * | 2010-06-16 | 2013-01-10 | Abbvie Inc. | Comparison of protein samples |
US9405884B2 (en) | 2010-06-16 | 2016-08-02 | Abbvie Inc. | Methods and systems for the analysis of protein samples |
JP2013536199A (ja) * | 2010-08-19 | 2013-09-19 | ピーイージー バイオサイエンシーズ インコーポレイテッド | 相乗性生体分子−ポリマーコンジュゲート |
MX358399B (es) * | 2010-11-12 | 2018-08-16 | Nektar Therapeutics | Conjugados de un resto de interleucina-2 y un polímero. |
KR101309566B1 (ko) | 2010-12-10 | 2013-09-17 | 포항공과대학교 산학협력단 | 히알루론산-단백질 컨쥬게이트 및 이의 제조 방법 |
WO2012140650A2 (en) | 2011-04-12 | 2012-10-18 | Hepacore Ltd. | Conjugates of carboxy polysaccharides with fibroblast growth factors and variants thereof |
WO2013020079A2 (en) * | 2011-08-04 | 2013-02-07 | Nektar Therapeutics | Conjugates of an il-11 moiety and a polymer |
EP2846822A2 (en) * | 2012-05-11 | 2015-03-18 | Prorec Bio AB | Method for diagnosis and treatment of prolactin associated disorders |
JP2016519108A (ja) | 2013-04-18 | 2016-06-30 | アルモ・バイオサイエンシーズ・インコーポレイテッド | インターロイキン−10を疾病及び疾患の治療に用いる方法 |
US20160068583A1 (en) * | 2013-04-24 | 2016-03-10 | Armo Biosciences, Inc. | Interleukin-10 Compositions and Uses Thereof |
AU2014281828B2 (en) | 2013-06-17 | 2019-05-09 | Armo Biosciences, Inc. | Method for assessing protein identity and stability |
JP6509867B2 (ja) | 2013-08-30 | 2019-05-08 | アルモ・バイオサイエンシーズ・インコーポレイテッド | 疾患及び障害を治療するためにインターロイキン−10を使用する方法 |
CA2928710A1 (en) | 2013-11-11 | 2015-05-14 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
UY35874A (es) * | 2013-12-12 | 2015-07-31 | Novartis Ag | Un proceso para la preparación de una composición de proteínas pegiladas |
CU20140003A7 (es) * | 2014-01-08 | 2015-08-27 | Ct De Inmunología Molecular Biofarmacuba | Conjugado que comprende eritropoyetina y una estructura polimérica ramificada |
WO2015187295A2 (en) | 2014-06-02 | 2015-12-10 | Armo Biosciences, Inc. | Methods of lowering serum cholesterol |
JP2017536098A (ja) | 2014-10-14 | 2017-12-07 | アルモ・バイオサイエンシーズ・インコーポレイテッド | インターロイキン−15組成物及びその使用 |
CN107106655A (zh) | 2014-10-22 | 2017-08-29 | 阿尔莫生物科技股份有限公司 | 使用白细胞介素‑10治疗疾病和病症的方法 |
PT3215193T (pt) | 2014-11-06 | 2023-12-15 | Pharmaessentia Corp | Regime de dosagem para interferão pegilado |
WO2016126615A1 (en) | 2015-02-03 | 2016-08-11 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
JP6937984B2 (ja) * | 2015-03-03 | 2021-09-22 | ナンシャ・バイオロジックス・(ホンコン)・リミテッドNansha Biologics (Hong Kong) Limited | ペグ化il−11の組成物および方法 |
CA2978330C (en) * | 2015-03-11 | 2024-01-09 | Nektar Therapeutics | Conjugates of an il-7 moiety and a polymer |
WO2016191587A1 (en) | 2015-05-28 | 2016-12-01 | Armo Biosciences, Inc. | Pegylated interleukin-10 for use in treating cancer |
CN108025040A (zh) | 2015-08-25 | 2018-05-11 | 阿尔莫生物科技股份有限公司 | 使用白介素-10治疗疾病和病症的方法 |
US9758786B2 (en) | 2016-02-09 | 2017-09-12 | Autotelic, Llc | Compositions and methods for treating pancreatic cancer |
AU2018270926C1 (en) | 2017-05-15 | 2022-10-27 | Nektar Therapeutics | Long-acting interleukin-15 receptor agonists and related immunotherapeutic compositions and methods |
EP3630162A1 (en) * | 2017-05-24 | 2020-04-08 | Novartis AG | Antibody-cytokine engrafted proteins and methods of use |
KR102649135B1 (ko) | 2017-07-11 | 2024-03-18 | 신톡스, 인크. | 비천연 뉴클레오티드의 도입 및 그의 방법 |
WO2019023295A1 (en) * | 2017-07-27 | 2019-01-31 | Saint Louis University | HUMAN EPIDERMAL GROWTH FACTOR MODIFIED BY FATTY ACID |
KR20240116580A (ko) | 2017-08-03 | 2024-07-29 | 신톡스, 인크. | 증식성 질환 및 감염성 질환의 치료를 위한 사이토카인 접합체 |
AU2018372167B2 (en) * | 2017-11-21 | 2023-12-07 | The Board Of Trustees Of The Leland Stanford Junior University | Partial agonists of interleukin-2 |
WO2019222295A1 (en) | 2018-05-14 | 2019-11-21 | Werewolf Therapeutics, Inc. | Activatable interleukin-2 polypeptides and methods of use thereof |
AU2019271149B2 (en) | 2018-05-14 | 2023-07-13 | Werewolf Therapeutics, Inc. | Activatable interleukin 12 polypeptides and methods of use thereof |
BR112021014415A2 (pt) | 2019-02-06 | 2021-09-21 | Synthorx, Inc. | Conjugados de il-2 e métodos de uso dos mesmos |
JP2022532217A (ja) | 2019-05-14 | 2022-07-13 | ウェアウルフ セラピューティクス, インコーポレイテッド | 分離部分及びその使用方法 |
BR112022009110A2 (pt) | 2019-11-14 | 2022-07-26 | Werewolf Therapeutics Inc | Polipeptídeos de citocina ativáveis e métodos de uso destes |
Family Cites Families (96)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4002531A (en) * | 1976-01-22 | 1977-01-11 | Pierce Chemical Company | Modifying enzymes with polyethylene glycol and product produced thereby |
GB1578348A (en) * | 1976-08-17 | 1980-11-05 | Pharmacia Ab | Products and a method for the therapeutic suppression of reaginic antibodies responsible for common allergic |
JPS6023084B2 (ja) * | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
US6610830B1 (en) * | 1980-07-01 | 2003-08-26 | Hoffman-La Roche Inc. | Microbial production of mature human leukocyte interferons |
FR2490675B1 (fr) * | 1980-09-25 | 1985-11-15 | Genentech Inc | Production microbienne d'interferon de fibroplaste humain |
DE3380726D1 (en) * | 1982-06-24 | 1989-11-23 | Japan Chem Res | Long-acting composition |
US4462940A (en) * | 1982-09-23 | 1984-07-31 | Cetus Corporation | Process for the recovery of human β-interferon-like polypeptides |
US4462946A (en) * | 1982-10-12 | 1984-07-31 | Goldsworthy Engineering, Inc. | Apparatus and method for producing reinforced plastic composite articles of non-uniform shape and non-uniform volume |
US4588585A (en) * | 1982-10-19 | 1986-05-13 | Cetus Corporation | Human recombinant cysteine depleted interferon-β muteins |
WO1985003934A1 (en) * | 1984-03-06 | 1985-09-12 | Takeda Chemical Industries, Ltd. | Chemically modified protein and process for its preparation |
US4732863A (en) * | 1984-12-31 | 1988-03-22 | University Of New Mexico | PEG-modified antibody with reduced affinity for cell surface Fc receptors |
US4766106A (en) * | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
US4917888A (en) * | 1985-06-26 | 1990-04-17 | Cetus Corporation | Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation |
US5206344A (en) * | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
US4816440A (en) * | 1985-09-26 | 1989-03-28 | Cetus Corporation | Stable formulation of biologically active proteins for parenteral injection |
US5037969A (en) * | 1986-07-03 | 1991-08-06 | Takeda Chemical Industries, Ltd. | Glycosyl derivatives and use thereof |
US4894330A (en) * | 1986-12-23 | 1990-01-16 | Cetus Corporation | Purification of recombinant beta-interferon incorporating RP-HPLC |
US5080891A (en) * | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
US5006333A (en) * | 1987-08-03 | 1991-04-09 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
JPH01128871A (ja) * | 1987-11-13 | 1989-05-22 | Kanzaki Paper Mfg Co Ltd | 感熱記録体用基材 |
US5004605A (en) * | 1987-12-10 | 1991-04-02 | Cetus Corporation | Low pH pharmaceutical compositions of recombinant β-interferon |
US4904584A (en) * | 1987-12-23 | 1990-02-27 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides |
US4847325A (en) * | 1988-01-20 | 1989-07-11 | Cetus Corporation | Conjugation of polymer to colony stimulating factor-1 |
US6132763A (en) * | 1988-10-20 | 2000-10-17 | Polymasc Pharmaceuticals Plc | Liposomes |
GB8824591D0 (en) * | 1988-10-20 | 1988-11-23 | Royal Free Hosp School Med | Fractionation process |
US5349052A (en) * | 1988-10-20 | 1994-09-20 | Royal Free Hospital School Of Medicine | Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor |
US5091176A (en) * | 1988-11-02 | 1992-02-25 | W. R. Grace & Co.-Conn. | Polymer-modified peptide drugs having enhanced biological and pharmacological activities |
US4902502A (en) * | 1989-01-23 | 1990-02-20 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
US5122614A (en) * | 1989-04-19 | 1992-06-16 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
US5324844A (en) * | 1989-04-19 | 1994-06-28 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
US5166322A (en) * | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
JPH04218000A (ja) * | 1990-02-13 | 1992-08-07 | Kirin Amgen Inc | 修飾ポリペプチド |
US5219564A (en) * | 1990-07-06 | 1993-06-15 | Enzon, Inc. | Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon |
JP3051145B2 (ja) * | 1990-08-28 | 2000-06-12 | 住友製薬株式会社 | 新規なポリエチレングリコール誘導体修飾ペプチド |
US5252714A (en) * | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
US5595732A (en) * | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
EP0586549B1 (en) * | 1991-05-10 | 2000-09-20 | Genentech, Inc. | Selecting ligand agonists and antagonists |
US5281698A (en) * | 1991-07-23 | 1994-01-25 | Cetus Oncology Corporation | Preparation of an activated polymer ester for protein conjugation |
US5362852A (en) * | 1991-09-27 | 1994-11-08 | Pfizer Inc. | Modified peptide derivatives conjugated at 2-hydroxyethylamine moieties |
ZA933926B (en) * | 1992-06-17 | 1994-01-03 | Amgen Inc | Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules |
US5382657A (en) * | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
US5581476A (en) * | 1993-01-28 | 1996-12-03 | Amgen Inc. | Computer-based methods and articles of manufacture for preparing G-CSF analogs |
US5395619A (en) * | 1993-03-03 | 1995-03-07 | Liposome Technology, Inc. | Lipid-polymer conjugates and liposomes |
CA2119089A1 (en) * | 1993-03-29 | 1994-09-30 | David Banner | Tumor necrosis factor muteins |
US5605976A (en) * | 1995-05-15 | 1997-02-25 | Enzon, Inc. | Method of preparing polyalkylene oxide carboxylic acids |
US5919455A (en) * | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5643575A (en) * | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5951974A (en) * | 1993-11-10 | 1999-09-14 | Enzon, Inc. | Interferon polymer conjugates |
KR960705579A (ko) * | 1993-11-10 | 1996-11-08 | 에릭에스. 딕커 | 개선된 인터페론 중합체 결합체(Improved interferon polymer conjugates) |
US5446090A (en) * | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
US5449090A (en) * | 1994-03-11 | 1995-09-12 | Martin Yale Industries, Inc. | Label dispenser |
DK0690127T3 (da) * | 1994-03-31 | 1999-05-03 | Amgen Inc | Sammensætninger og fremgangsmåder til stimulering af megakaryocytvækst og -differentiering |
US5889153A (en) * | 1994-05-20 | 1999-03-30 | Hisamitsu Pharmaceutical Co., Inc. | Protein or polypeptide, method for producing the same and intermediate compound therefor |
US5730990A (en) * | 1994-06-24 | 1998-03-24 | Enzon, Inc. | Non-antigenic amine derived polymers and polymer conjugates |
US20030053982A1 (en) * | 1994-09-26 | 2003-03-20 | Kinstler Olaf B. | N-terminally chemically modified protein compositions and methods |
US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
US5738846A (en) * | 1994-11-10 | 1998-04-14 | Enzon, Inc. | Interferon polymer conjugates and process for preparing the same |
US5770577A (en) * | 1994-11-14 | 1998-06-23 | Amgen Inc. | BDNF and NT-3 polypeptides selectively linked to polyethylene glycol |
US5932462A (en) * | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
WO2000023144A1 (en) | 1995-04-23 | 2000-04-27 | Electromagnetic Bracing Systems, Inc. | Transdermal active drug delivery system and method |
US5756593A (en) * | 1995-05-15 | 1998-05-26 | Enzon, Inc. | Method of preparing polyalkyene oxide carboxylic acids |
US5672662A (en) * | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
US5747639A (en) * | 1996-03-06 | 1998-05-05 | Amgen Boulder Inc. | Use of hydrophobic interaction chromatography to purify polyethylene glycols |
EP1731174A3 (en) * | 1996-08-02 | 2007-01-17 | Ortho-McNeil Pharmaceutical, Inc. | Polypeptides having a covalently bound N-terminal polyethylene glycol via hydrazone or oxime bond |
JP3814903B2 (ja) * | 1996-12-25 | 2006-08-30 | 株式会社日立製作所 | 映像・データ表示方法及び装置 |
US5990237A (en) * | 1997-05-21 | 1999-11-23 | Shearwater Polymers, Inc. | Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines |
NZ502375A (en) * | 1997-07-14 | 2001-11-30 | Bolder Biotechnology Inc | The addition of non-natural cysteine derivatives to cause the protein to act as antagonists of the GH family |
US6017876A (en) * | 1997-08-15 | 2000-01-25 | Amgen Inc. | Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity |
US5985263A (en) * | 1997-12-19 | 1999-11-16 | Enzon, Inc. | Substantially pure histidine-linked protein polymer conjugates |
US5981709A (en) * | 1997-12-19 | 1999-11-09 | Enzon, Inc. | α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same |
JP2002505338A (ja) * | 1998-03-05 | 2002-02-19 | カイロン コーポレイション | 生物学的に活性な分子の血清半減期を増加するための方法 |
DK0985697T3 (da) * | 1998-03-24 | 2006-05-15 | Nof Corp | Oxiranderivater og fremgangsmåde til fremstilling deraf |
ATE275422T1 (de) * | 1998-04-28 | 2004-09-15 | Applied Research Systems | Konjugate aus polyole und beta-interferon |
DE69943205D1 (de) * | 1998-08-06 | 2011-03-31 | Mountain View Pharmaceuticals | Peg-uricase Konjugate und Verwendung davon |
PT1656952E (pt) * | 1998-10-16 | 2014-02-21 | Biogen Idec Inc | Conjugados de polietileno-glicol e interferão beta 1a e as suas utilizações |
JO2291B1 (en) * | 1999-07-02 | 2005-09-12 | اف . هوفمان لاروش ايه جي | Erythropoietin derivatives |
ATE522563T1 (de) * | 1999-12-24 | 2011-09-15 | Kyowa Hakko Kirin Co Ltd | Verzweigte polyalkylenglykole |
EP2295450B1 (en) * | 2000-09-29 | 2015-01-28 | Merck Sharp & Dohme Corp. | Pegylated interleukin-10 |
US6887462B2 (en) * | 2001-04-09 | 2005-05-03 | Chiron Corporation | HSA-free formulations of interferon-beta |
US6908963B2 (en) * | 2001-10-09 | 2005-06-21 | Nektar Therapeutics Al, Corporation | Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith |
JP2005517648A (ja) | 2001-12-07 | 2005-06-16 | インターミューン インコーポレイテッド | 肝炎ウイルス感染症を治療するための組成物および方法 |
AU2002357806A1 (en) * | 2001-12-11 | 2003-06-23 | Sun Bio, Inc. | Novel monofunctional polyethylene glycol aldehydes |
GEP20064024B (en) * | 2002-01-18 | 2007-01-10 | Biogen Idec Inc | Polyalkylene glycol comprising a radical for conjugation of biologically active compound |
AU2003270454B2 (en) * | 2002-09-09 | 2010-05-20 | Nektar Therapeutics | Water-soluble polymer alkanals |
US8129330B2 (en) * | 2002-09-30 | 2012-03-06 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof |
US20040062748A1 (en) * | 2002-09-30 | 2004-04-01 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof |
CA2504267A1 (en) * | 2002-11-18 | 2004-06-03 | Maxygen, Inc. | Interferon-alpha polypeptides and conjugates |
US8003117B2 (en) * | 2002-11-20 | 2011-08-23 | Nof Corporation | Polyalkylene glycol derivative and modified bio-related substance |
US20040142870A1 (en) * | 2002-11-20 | 2004-07-22 | Finn Rory F. | N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof |
US8828373B2 (en) * | 2002-11-20 | 2014-09-09 | Nof Corporation | Polyalkylene glycol derivative and modified bio-related substance |
TWI281864B (en) * | 2002-11-20 | 2007-06-01 | Pharmacia Corp | N-terminally monopegylated human growth hormone conjugates and process for their preparation |
JP4412461B2 (ja) * | 2002-11-20 | 2010-02-10 | 日油株式会社 | 修飾された生体関連物質、その製造方法および中間体 |
EP1628618A4 (en) * | 2002-12-26 | 2009-09-09 | Mountain View Pharmaceuticals | POLYMER CONJUGATES OF CYTOKINES, CHEMOKINS, GROWTH FACTORS, POLYPEPTIDE HORMONES AND ANTAGONISTS THEREOF WITH PRESERVED RECEPTOR BINDING ACTIVITY |
TWI406672B (zh) * | 2002-12-26 | 2013-09-01 | Mountain View Pharmaceuticals | 生物效力增進的β干擾素聚合物共軛體 |
US20070185135A1 (en) * | 2005-12-30 | 2007-08-09 | Pharmaessentia Corp. | Drug-Polymer Conjugates |
-
2003
- 2003-12-23 EP EP03808555A patent/EP1628618A4/en not_active Withdrawn
- 2003-12-23 TW TW092136592A patent/TWI364295B/zh not_active IP Right Cessation
- 2003-12-23 WO PCT/US2003/041162 patent/WO2004060300A2/en active Search and Examination
- 2003-12-23 MX MXPA05006945A patent/MXPA05006945A/es active IP Right Grant
- 2003-12-23 CA CA002511815A patent/CA2511815A1/en not_active Abandoned
- 2003-12-23 BR BR0317752-1A patent/BR0317752A/pt not_active Application Discontinuation
- 2003-12-23 EA EA200501051A patent/EA013535B1/ru not_active IP Right Cessation
- 2003-12-23 KR KR1020057012120A patent/KR101162908B1/ko active IP Right Grant
- 2003-12-23 JP JP2005508614A patent/JP2006519170A/ja active Pending
- 2003-12-23 RS YUP-2005/0501A patent/RS20050501A/sr unknown
- 2003-12-23 AU AU2003303636A patent/AU2003303636B2/en not_active Ceased
- 2003-12-23 US US10/743,295 patent/US20040136952A1/en not_active Abandoned
- 2003-12-23 NZ NZ541122A patent/NZ541122A/en not_active IP Right Cessation
- 2003-12-23 GE GEAP20038911A patent/GEP20084487B/en unknown
- 2003-12-23 PL PL380269A patent/PL380269A1/pl not_active Application Discontinuation
- 2003-12-23 PL PL396711A patent/PL396711A1/pl unknown
-
2005
- 2005-07-04 CR CR7895A patent/CR7895A/es unknown
- 2005-07-04 IS IS7931A patent/IS7931A/is unknown
- 2005-07-20 NO NO20053555A patent/NO20053555L/no not_active Application Discontinuation
- 2005-07-20 EC EC2005005931A patent/ECSP055931A/es unknown
-
2007
- 2007-03-27 US US11/727,641 patent/US20080058246A1/en not_active Abandoned
-
2010
- 2010-09-30 JP JP2010221122A patent/JP2011051991A/ja active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2549702C2 (ru) * | 2008-12-17 | 2015-04-27 | Мерк Шарп И Доум Корп., | Получение и применение моно- и ди-пэг il-10 |
EA029942B1 (ru) * | 2014-06-16 | 2018-06-29 | Общество С Ограниченной Ответственностью "Форт" (Ооо "Форт") | Стабильная фармацевтическая композиция на основе конъюгатов биологически активных белков с полиэтиленгликолем, содержащих азогруппу |
Also Published As
Publication number | Publication date |
---|---|
AU2003303636B2 (en) | 2010-08-05 |
JP2011051991A (ja) | 2011-03-17 |
WO2004060300A2 (en) | 2004-07-22 |
KR20050089860A (ko) | 2005-09-08 |
CR7895A (es) | 2007-03-21 |
TWI364295B (en) | 2012-05-21 |
PL396711A1 (pl) | 2011-12-19 |
EA013535B1 (ru) | 2010-06-30 |
BR0317752A (pt) | 2005-11-22 |
GEP20084487B (en) | 2008-09-25 |
IS7931A (is) | 2005-07-04 |
NO20053555D0 (no) | 2005-07-20 |
WO2004060300A3 (en) | 2006-07-13 |
AU2003303636A1 (en) | 2004-07-29 |
KR101162908B1 (ko) | 2012-07-06 |
US20080058246A1 (en) | 2008-03-06 |
ECSP055931A (es) | 2006-11-24 |
PL380269A1 (pl) | 2007-01-08 |
NZ541122A (en) | 2008-09-26 |
TW200501979A (en) | 2005-01-16 |
RS20050501A (en) | 2007-08-03 |
EP1628618A4 (en) | 2009-09-09 |
NO20053555L (no) | 2005-09-23 |
MXPA05006945A (es) | 2005-12-14 |
JP2006519170A (ja) | 2006-08-24 |
EP1628618A2 (en) | 2006-03-01 |
CA2511815A1 (en) | 2004-07-22 |
US20040136952A1 (en) | 2004-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200501051A1 (ru) | Полимерный конъюгат биоактивного компонента ( варианты ), способ его получения и использования, фармацевтические продукты на его основе | |
EA200501050A1 (ru) | ПОЛИМЕРНЫЙ КОНЪЮГАТ МОДИФИКАЦИЙ ИНТЕРФЕРОНА-β, ФАРМАЦЕВТИЧЕСКИЕ ПРОДУКТЫ НА ЕГО ОСНОВЕ И СПОСОБ ИХ ПОЛУЧЕНИЯ | |
MXPA05003394A (es) | Conjugados de polimero con antigenicidad disminuida, metodos de preparacion y usos de estos. | |
GEP20074267B (en) | Receptor nucleic acids and polypeptides | |
EG25613A (en) | Thienopyrimidinediones and their use in the modulation of autoimmune disease | |
WO2004060405A3 (en) | Tissue reactive compounds and compositions and uses thereof | |
WO2005023294A3 (en) | Polyacetal drug conjugates as release system | |
NZ593986A (en) | Compositions comprising a protein and a carrier for topical diagnostic and therapeutic transport | |
BR122016022033B8 (pt) | conjugados de polipeptídeo isolado apresentando atividade pró-coagulante de fator viii, seu uso e composição farmacêutica | |
IL217265A (en) | Use of trans-membrane plant, calcium modulator, and taci immunoglobulin proteins, for the preparation of a drug for the treatment of s'sjogren syndrome | |
UA103758C2 (ru) | Конъюгаты олигомеров инсулина, их композиции и применение | |
WO2005039641A3 (en) | Biomacromolecule polymer conjugates | |
RU2009122976A (ru) | Конъюгат полиэтиленгликоля-г-ксф | |
UA91325C2 (ru) | Полимерные конъюгаты цитокинов, хемокинов, факторов роста, полипептидных гормонов и их антагонистов с сохраненной активностью рецепторного связывания | |
DE602004006024D1 (de) | Pharmazeutische zusammensetzung mit einem zink/hyaluronat-komplex zur behandlung von multipler sklerose | |
AR073408A2 (es) | Conjugados polimericos de citoquinas, quimiocinas, factores de crecimiento, hormonas polipeptidicas y sus antagonistas con actividad conservada de union al receptor | |
AU2003256730A8 (en) | Preparation of lactic acid derivatives and their use | |
US20160130484A1 (en) | Multi-component adhesive for producing an adhesive hydrogel | |
UA86002C2 (ru) | ПОЛИМЕРНЫЕ КОНЪЮГАТЫ С УМЕНЬШЕННОЙ АНТИГЕННОСТЬЮ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ИХ ПРИМЕНЕНИЕ<tab> |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ KG MD TJ TM |
|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): BY KZ RU |
|
NF4A | Restoration of lapsed right to a eurasian patent |
Designated state(s): BY KZ RU |
|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): BY KZ |
|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): RU |